<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00684528</url>
  </required_header>
  <id_info>
    <org_study_id>jfr_il0801</org_study_id>
    <nct_id>NCT00684528</nct_id>
  </id_info>
  <brief_title>A Double-Blind, Randomized, Active-Comparator (Metformin) Controlled, Clinical Trial to Study the Efficacy and Safety of the Strategy to Start Patients With Type 2 Diabetes Mellitus on Janumet™ Compared to Metformin</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>Meir Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Clalit Health Services</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Meir Medical Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Comparison between the effectiveness of one anti-diabetic drug (Metformin, To combination of&#xD;
      this drug and additional drug (Janufer), In the community setting.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a randomized, double-blind, active-comparator (metformin) controlled study in&#xD;
      drug-naïve patients with T2DM who have an HbA1c ≥ 7.5%. The duration of the study is 55&#xD;
      weeks, which will include a 1-week screening period (Visit 1 to Visit 2) and a 54 week&#xD;
      double-blind, active treatment period. At Visit 2/Day 1 patients who meet all enrollment&#xD;
      criteria will be randomized in a 1:1 ratio to one of two active treatment groups: 1. JANUMET™&#xD;
      (fixed-dose combination sitagliptin/metformin) or 2. metformin. The starting fixed-dose&#xD;
      combination of sitagliptin/metformin will be 50/500 mg administered twice-daily and then&#xD;
      up-titrated to a dose of 50/1000 mg b.i.d. over 4 weeks. The starting dose of metformin will&#xD;
      be 500 mg twice-daily and then up-titrated to a dose of 1000 mg b.i.d. over 4 weeks. Patients&#xD;
      who can not tolerate JANUMET™ at a dose of at least 50/500 mg b.i.d. or metformin at a dose&#xD;
      of at least 500 mg b.i.d. 6 weeks after randomization and throughout the study will be&#xD;
      discontinued. During the double-blind treatment period patients will remain on the study&#xD;
      medication, but investigators are allowed to add other antihyperglycemic agents to improve&#xD;
      glycemic control as necessary. The investigator can schedule additional visits to initiate&#xD;
      additional antihyperglycemic agents or monitor glycemic control at any time during the study&#xD;
      period. There will be no fixed visit schedule, but 7 clinical visits are recommended. It is&#xD;
      also recommended to perform the first visit on active treatment 6 weeks after randomization&#xD;
      and after this visit to schedule visits every 3 months. All clinical and lab data can be&#xD;
      obtained using the &quot;Clalit health care information system&quot;.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>June 2008</start_date>
  <completion_date type="Anticipated">December 2012</completion_date>
  <primary_completion_date type="Actual">December 2011</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The efficacy and safety of community based study in diabetic patients, comparing Metformin to Metformin + Janufer.</measure>
    <time_frame>54 weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>The efficacy and safety of Metformin VS Metformin + Janufer in the community setting</measure>
    <time_frame>2010</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">1000</enrollment>
  <condition>Diabetes Type 2</condition>
  <arm_group>
    <arm_group_label>a</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>This group will receive Metformin and placebo.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The second arm will receive Metformin and Januvia</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Metformin 1500 mg daily</intervention_name>
    <description>500 mg thrice daily</description>
    <arm_group_label>2</arm_group_label>
    <arm_group_label>a</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Metformin + Janufer (Janumet)</intervention_name>
    <description>Titration up to 1500/150 mg daily</description>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  All laboratory measurements are to be performed after an overnight fast ≥ 10 hours in&#xD;
             duration. Patients with laboratory screening values/findings not meeting protocol&#xD;
             inclusion criteria may, at the discretion of the investigator, have one repeat&#xD;
             determination performed. If the repeat value satisfies the criterion they may continue&#xD;
             in the screening process. Only the laboratory test not meeting inclusion should be&#xD;
             repeated (not the entire panel).&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        Glucose Metabolism and Therapy Criteria&#xD;
&#xD;
          -  Patient has a history of type 1 diabetes mellitus or history of ketoacidosis. Patients&#xD;
             Requiring Specific Treatments&#xD;
&#xD;
          -  Patient has symptomatic hyperglycemia requiring immediate initiation of insulin&#xD;
             therapy.&#xD;
&#xD;
          -  Patient has a history of intolerance or hypersensitivity to metformin or sitagliptin&#xD;
             or has any contraindication to use metformin.&#xD;
&#xD;
        Concomitant Disease of Organs and Systems&#xD;
&#xD;
          -  Patient has a medical history of active liver disease (excluding hepatic steatosis).&#xD;
&#xD;
          -  Patient has severe active peripheral vascular disease (e.g., manifested by&#xD;
             claudication with minimal activity, a non-healing ischemic ulcer, or disease which is&#xD;
             likely to require intervention such as with bypass or angioplasty).&#xD;
&#xD;
          -  Patient has unstable or acute congestive heart failure.&#xD;
&#xD;
          -  Patient has a history of malignancy without documentation of remission/cure. Other&#xD;
             Criteria&#xD;
&#xD;
          -  Patient is pregnant, has a positive urine pregnancy test at Visit 1, is expecting to&#xD;
             conceive within the projected duration of the study, or is breast feeding.&#xD;
&#xD;
        Exclusion Criteria Based on Lab Abnormalities&#xD;
&#xD;
          -  Patient has increased serum-creatinine and/or decreased estimated creatinine&#xD;
             clearance.&#xD;
&#xD;
          -  If screening labs are repeated, the last laboratory draw/result should be used for&#xD;
             inclusion.§ Either elevated Creatinine or decreased estimated creatinine clearance&#xD;
             lead to exclusion of the patient.&#xD;
&#xD;
          -  Patients whose serum creatinine does not meet the exclusion criteria, but whose&#xD;
             estimated creatinine clearance is &lt;60 mL/min but ≥50 mL/min, may have a measured&#xD;
             creatinine clearance (i.e., based upon a 24-hour urine collection). These patients may&#xD;
             be eligible if their measured creatinine clearance is ≥60 mL/min.&#xD;
&#xD;
        At Visit 2&#xD;
&#xD;
          -  Patient has a site fingerstick glucose &lt;130 mg/dL (7.2 mmol/L) or &gt;320 mg/dL (17.8&#xD;
             mmol/L).&#xD;
&#xD;
        Note: If the patient meets this exclusion criterion AND the investigator believes that the&#xD;
        value does not reflect the patient's recent glycemic control based upon recent SBGM values&#xD;
        and/or the Visit 1 FPG value, the patient should not be excluded at this time. The current&#xD;
        visit should be changed to an &quot;Unscheduled visit&quot; and the patient should be rescheduled for&#xD;
        Visit 2. If, at the rescheduled Visit 2, the patient meets this exclusion criterion, the&#xD;
        patient MUST be excluded.&#xD;
&#xD;
          -  Patient has a positive urine pregnancy test.&#xD;
&#xD;
          -  Patient developed a new medical condition, suffered a change in status of an&#xD;
             established medical condition, developed a laboratory abnormality, or required a new&#xD;
             treatment or medication between Visit 1 and Visit 2 which meets any previously&#xD;
             described study exclusion criterion.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Joel Zinger, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>clali health organization</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Niky Liberman, MD</last_name>
    <phone>972-3692-3316</phone>
    <email>nikyli@clalit.org.il</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Lotan Shilo, MD</last_name>
    <phone>972-9747-2170</phone>
    <email>shilolo@clalit.org.il</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Clalit Health services center</name>
      <address>
        <city>Tel Aviv</city>
        <zip>62098</zip>
        <country>Israel</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Zinger</last_name>
      <phone>972-5062-63652</phone>
    </contact>
    <investigator>
      <last_name>Zinger Joel, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Israel</country>
  </location_countries>
  <reference>
    <citation>Mistry GC, Maes AL, Lasseter KC, Davies MJ, Gottesdiener KM, Wagner JA, Herman GA. Effect of sitagliptin, a dipeptidyl peptidase-4 inhibitor, on blood pressure in nondiabetic patients with mild to moderate hypertension. J Clin Pharmacol. 2008 May;48(5):592-8. doi: 10.1177/0091270008316885. Epub 2008 Mar 19.</citation>
    <PMID>18353996</PMID>
  </reference>
  <results_reference>
    <citation>Scott R, Loeys T, Davies MJ, Engel SS; Sitagliptin Study 801 Group. Efficacy and safety of sitagliptin when added to ongoing metformin therapy in patients with type 2 diabetes. Diabetes Obes Metab. 2008 Sep;10(10):959-69. doi: 10.1111/j.1463-1326.2007.00839.x. Epub 2008 Jan 14.</citation>
    <PMID>18201203</PMID>
  </results_reference>
  <verification_date>March 2012</verification_date>
  <study_first_submitted>May 21, 2008</study_first_submitted>
  <study_first_submitted_qc>May 23, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 26, 2008</study_first_posted>
  <last_update_submitted>March 16, 2012</last_update_submitted>
  <last_update_submitted_qc>March 16, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 19, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>DM 2</keyword>
  <keyword>Metformin</keyword>
  <keyword>Januvia</keyword>
  <keyword>Community setting</keyword>
  <keyword>newly diagnosed diadetics, or diabetes patients not treated during the last year</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Metformin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

